HURWITZ EDWARD
Known title: DirectorCIK: 0001211840
HURWITZ EDWARD's purchase track record
HURWITZ EDWARD has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/30/2023 | MGNX | $74K | +53.5% | +250.8% | +12.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MGNX | ▲ Buy | Option Exercise | 3,750 | — | 5/18/2026 | View on chart |
| MGNX | ▲ Buy | Option Exercise | 6,500 | — | 5/20/2025 | View on chart |
| MGNX | ▲ Buy | Option Exercise | 4,500 | $0 | 5/20/2024 | View on chart |
| MGNX | ▲ Buy | Open Market | 15,000 | $74K | 8/30/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
MGNX mentioned in medical stock sector review
MacroGenics was included in a recent Yahoo Finance article examining the performance of medical stocks this year. The stock is currently trading near its 52-week low, with technical indicators showing weakness near key support levels. This context highlights the broader sector trends affecting the company's valuation.
MGNX mentioned in medical stock sector review. MacroGenics was included in a recent Yahoo Finance article examining the performance of medical stocks this year. The stock is currently trading near its 52-week low, with technical indicators showing weakness near key support levels. This context highlights the broader sector trends affecting the company's valuation.